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Abstract
Law no. 12,401/2011 and Decree no. 7,508/2011 are 
celebrated, among other reasons, for introducing 
new rules for the pharmaceutical assistance policy 
that would have the potential to streamline the 
judicialization of health care in Brazil. This study 
aims to analyze the effects of the universal access 
to the comprehensive pharmaceutical assistance 
established by these legislations considering the 
judicialization of medicines in the state of Minas 
Gerais from 1999 to 2009. This is a retrospective 
study that analyzes the legal disputes deferred 
against Minas Gerais during the period. If the 
criteria established in 2011 were normalized and 
respected by the Judiciary in this interval, between 
68.84% and 85.77% of the medicines judicialized in 
Minas Gerais would have been rejected. However, 
despite having the potential to streamline the 
judicialization, the legislations do not seem to have 
influenced the judicial decisions permanently.
Keywords: Judicialization of Health; Pharmaceutical 
Assistance; Brazilian National Health System; 
Health Policy.
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Resumo
A Lei nº 12.401/2011 e o Decreto nº 7.508/2011 são 
celebrados, entre outros motivos, por introduzir 
regras inéditas para a política de assistência 
farmacêutica que teriam o potencial de racionalizar 
a judicialização da saúde no Brasil. Este estudo 
visa analisar qual seria o impacto da observância 
dos critérios de acesso universal à assistência 
farmacêutica integral, delimitados pelos marcos 
normativos, no cenário da judicialização de 
medicamentos em Minas Gerais de 1999 a 2009. 
Trata-se de um estudo retrospectivo que analisa 
os litígios judiciais deferidos contra o estado 
no período. Se os critérios instituídos em 2011 
estivessem normalizados e fossem acatados pelo 
Judiciário no intervalo em pauta, entre 68,84% 
e 85,77% dos medicamentos judicializados em 
Minas Gerais teriam sido indeferidos. Contudo, 
apesar de demonstrar potencial para racionalizar a 
judicialização, as normativas ainda não parecerem 
ter influenciado as decisões em saúde de forma 
determinante.
Palavras-chave: Judicialização da Saúde; Assistência 
Farmacêutica; Sistema Único de Saúde; Política de 
Saúde.
Introduction
The medicines are the main object of legal 
disputes in health care in Brazil (Aumentam…, 2017). 
Among the main acclaimed arguments for their 
judicialization, universality and comprehensiveness 
of the constitutional right to health care stand out 
(Balestra Neto, 2015). The difficulty in delimiting the 
specific outlines of these principles, as well as the 
consolidation of a judicial interpretation unable to 
situate them in a more coherent and harmonious way 
with the development process of all the structures 
of the Brazilian National Health System (SUS) were 
key elements for the exacerbated growth in the 
judicialization of health care in the country (Aith 
et al., 2014; Bittencourt, 2016).
The significant volume of disputes over health 
care at the end of the 2000s and its financial impact 
showed some of the contradictions of judicialization 
and the consequent need for interventions in order 
to streamline it and detain its expansion (Balestra 
Neto, 2015).
One of the institutional initiatives in this 
direction was the creation of a new legislation 
for the pharmaceutical assistance of SUS, arising 
from changes promoted by Law no. 12,401, of April 
28, 2011, and by Decree no. 7,508, of June 28 of the 
same year (Brasil, 2011a, 2011b). These legislations 
were created after the Public Hearing no. 4 held by 
the Supreme Court in 2009 and renewed structures 
and central criteria to ensure the pharmaceutical 
assistance in the country. After delimiting the scope 
of comprehensiveness (Aith et al., 2014; Balestra 
Neto, 2015) and the conditions for the universal and 
equitable access to the pharmaceutical assistance 
within SUS (Siqueira, 2015), the legislations were 
announced with the aim to focus on the dynamics 
of the judicialization of health care.
Law no. 12,401/2011 created the National 
Commission for Health Technology Incorporation 
of SUS (Conitec) and defined in its article 1, which 
includes article 19-M in Law no. 8,080/1990, that the 
comprehensive therapeutic assistance includes the 
“dispensation of medicines and products of interest 
for health care, whose prescription is in accordance 
with the guidelines defined in the therapeutic 
clinical protocol” and the supply of therapeutic 
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procedures selected by the federal manager of SUS. 
The legislation establishes that, in the absence of a 
clinical protocol, the relation of medicines defined 
nationally (National Relation of Essential Medicines 
– Rename) must be observed, as well as the relation 
defined by states or by municipalities (Brasil, 2011a).
Decree no. 7,508/2011 instituted Health Care 
Networks as a model for organization of SUS 
and established cumulative criteria that require 
universal and equal access to the pharmaceutical 
assistance, namely:
I – the patient must be assisted by health actions 
and services provided by SUS; II – the medicine 
must have been prescribed by health professionals 
in the regular exercise of their functions in SUS; 
III – the prescription must be in accordance with 
Rename and Clinical Protocols and Therapeutic 
Guidelines or with the state, district or municipal 
complementary specific relation of medicines; 
and IV – the dispensation must have occurred in 
units indicated by the directors of SUS. (Brasil, 
2011b, art. 28)
The clarification of parameters about the 
organization of the public health policy and the 
principles of SUS would theoretically ensure greater 
streamlining for judicial activities (Ramos; Diniz; 
Madureira, 2015). But at a time of debate about the 
judicialization of the right to health care in the 
country, when a large amount of actions and the 
prominence of the Judiciary is observed (Guimarães, 
2014), would these norms have the ability to 
streamline the judicialization of health?
In order to contribute to the debate, this study 
verified the potential to streamline the criteria of 
universal access to comprehensive pharmaceutical 
assistance, established by Law no. 12,401/2011 and 
by Decree no. 7,508/2011, in the judicialization of 
health after analyzing its impact on the first decade 
of the judicialization of the access to medicines in 
Minas Gerais, between 1999 and 2009.
Methods
This is a retrospective and descriptive study 
based on the records of the 6,112 legal proceedings 
in health deferred against the State Secretariat of 
Health of Minas Gerais (SES/MG) between October 
1999 and October 2009. The database containing 
such records was created by the Research Group on 
Health Economics at the Universidade Federal de 
Minas Gerais (EPG/UFMG) from documentation of 
legal proceedings provided by SES/MG. The database 
contains variables with information about the 
legal aspect of the proceeding, the beneficiary, the 
author, the legal representative, the defendant, the 
service, the medicine and the possible proceedings, 
materials and inputs.
To conduct the analysis of this study, we 
selected variables that contained information 
about the clinical care (presence of logo of SUS in 
the prescription, nature of the service organization 
and professional record of the prescriber) and 
the medicine (year of the process, medicine, 
active ingredient, classification – if medicine, 
cosmeceutical, nutritional support or another – and 
inclusion into Rename 2013). The medicines with 
undefined active ingredients and those classified 
as cosmeceuticals, nutritional support or other 
were excluded.
The variables selected for the study were 
confronted with the criteria for access to the 
pharmaceutical assistance imposed in 2011 
as follows: when the care was provided in an 
establishment of public nature, it was considered 
that the patient was assisted by health actions 
and services within SUS (criterion I); in the 
case of prescription with the logo of SUS, we 
understood that the medicine was prescribed 
by a health professional in the regular exercise 
of his/her functions in SUS (criterion II); when 
the medicine demanded was in Rename, it was 
considered that the limitation period was in 
accordance with the Clinical Protocols and 
Therapeutic Guidelines (PCDT) and/or Rename 
(criterion III), since the legislations require 
compliance with the Relation in the absence 
of clinical protocols, and few of them had been 
adopted/updated until 2010 (Pepe, 2011). As 
judicialization precedes the dispensation of 
medicines, the IV criterion, “the dispensation 
must have occurred in units indicated by the 
directors of SUS” was disregarded.
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When there was not enough information about the 
care and prescription that originated the dispensation 
of a drug, Rename 2013 was considered a reference 
for conducting the analysis, since this information 
was available to all medicines selected for this study.
Considering the possibility of hiring private 
services within SUS, the classification adopted 
in this study according to the suitability of the 
criteria defined by the Decree no. 7,508/2011, 
together with Law no. 12,401/2011 was set as shown 
in Chart 1. From this classification, the absolute and 
relative frequencies of distribution of judicialized 
medicines were calculated among the groups of 
defined criteria.
Chart 1 – Classification adopted to assess the adequacy of judicialized medicines to the criteria for the access 
to the pharmaceutical assistance
Classification 
Criterion I – the patient must be 
assisted by health actions and 
services of SUS
Criterion II – the medicine must 
have been prescribed by health 
professionals in the regular exercise 
of their functions in SUS
Criterion III – the 
prescription must be in 
accordance with PCDT 
and/or Rename
Adequate (1)
Organization of public, non-
informed or private nature
Prescription with logo of SUS 
Medicine included in 
Rename
Adequate (2) Organization of public nature 
No information about the logo of SUS 
or prescription without logo of SUS
Medicine included in 
Rename
Impossible to classify 
Organization of non-informed or 
private nature
No information about the logo of SUS
Medicine included in 
Rename
Inadequate (1)
Organization of non-informed or 
private nature
Prescription with logo of SUS
Medicine included in 
Rename
Inadequate (2)
Organization of public, non-
informed or private nature
Prescription without or with the logo 
of SUS or without information about 
its existence 
Medicine NOT included in 
Rename
The limitations of the study include: the lack of 
assessment of PCDT, since it is not always a medicine 
that is present in Rename will be judicialized for use 
according to clinical protocols (off label use); the 
lack of assessment of the inclusion of medicines 
in the Relation to Medicines of the State of Minas 
Gerais and in the Municipal Relations of Essential 
Medicines of the municipalities of Minas Gerais, 
which were supportive defendants of the state of 
Minas Gerais, since, according to the legislations, 
the prescription must be in compliance with one of 
these three official lists of medicines; the assessment 
of the inclusion criterion in Rename having as 
reference the Relation of 2013 and not that into force 
on the date of the court order; and the possibility of 
misuse of the prescription of SUS to patients treated 
in private institutions that were not hired by the 
public health system.
This study was conducted as part of the master’s 
thesis of the first author, supported by Capes. 
In addition, it integrates the projects “Impact of 
lawsuits on the national pharmaceutical assistance 
policy: clinical management and medicalization of 
justice” (CNPq/EPG/FM/UFMG) and “Budget impact 
analysis in the Brazilian National Health System 
(SUS) of the most demanded medicines by judicial 
means in Pharmaceutical Assistance Programs 
“(Fapemig no. 14/2013, Research Program for SUS 
(PPSUS MS/CNPq Fapemig/SES)), whose approval 
by the Research Ethics Committee of UFMG was 
obtained by Opinion no. Etic 292/08.
Results
Of the 11,507 items deferred as pharmaceuticals 
in lawsuits against the SES/MG from October 1999 
to October 2009, 10,051 medicines were selected 
for the study. Among these, 773 (7.69%) medicines 
were classified as adequate and 6,919 (68.84%) 
as inadequate to the criteria for access to the 
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pharmaceutical assistance imposed in 2011. Table 
1 shows the distribution of medicines according to 
the classification proposed.
Table 1 – Distribution of 10,051 judicialized medicines 
according to the classification of adequacy to the 
criteria for access to the pharmaceutical assistance, 
Minas Gerais, 1999-2009
Classification Number of medicines Percentage (%)
Adequate (1) 406
7.69
Adequate (2) 367
Impossible to 
classify
2,359 23.47
Inadequate (1) 1,985
68.84
Inadequate (2) 4,934
TOTAL 10,051 100.00
Source: Banco de Dados Judicialização, GPES/UFMG, 2018
Of the 10,051 medicines, 5,580 (55.52%) were 
related to at least one information about the nature 
of the establishment or existence of the logo of SUS 
in the prescription, then we opted for the additional 
analysis of this group of drugs, so the classification 
was not based on data related only to the criterion 
III. According to these parameters, the inadequacy to 
the criteria increased to 85.77% regarding medicines, 
while adequacy increased to 13.85%.
The classification was also applied to each year 
of the period to investigate differences, similarities 
and trends. Between 1999 and 2002, the number of 
legal proceedings deferred against the state of Minas 
Gerais was lower than 100, so we chose to consider 
the period from 2003 to 2009 for the analysis of 
temporal trend. Table 2 shows the result of the 
classification adopted and the number of judicialized 
medicines for each year studied.
The proportion of medicines adequate to the 
criteria for access to the pharmaceutical assistance 
increased randomly between 2003 and 2009, against 
a steady increase in the proportion of medicines 
classified as inadequate to the criteria. In addition, 
we observed an inverse decreasing trend of the lack 
of information about health care over the years. 
Figure 1 shows the behavior almost mirrored the 
curves relating to the classifications “Impossible 
to classify” and “inadequate.”
Table 2 – Distribution of 10,051 medicines deferred in legal proceedings against the state, per year, according to 
the classification of adequacy to the criteria for access to the pharmaceutical assistance, Minas Gerais, 1999-2009
Year
Quantity of 
judicialized medicines
Proportion of 
medicines adequate to 
the criteria (%)
Proportion of medicines 
impossible to classify (%)
Proportion of medicines 
inadequate to the criteria (%)
1999 2 50.00 0.00 50.00
2000 15 20.00 33.33 46.67
2001 3 33.33 66.67 0.00
2002 54 1.85 59.26 38.89
2003 113 2.65 37.17 60.18
2004 315 3.81 35.87 60.32
2005 835 7.90 25.75 66.35
2006 1,614 6.38 26.83 66.79
2007 2,489 6.39 24.59 69.02
2008 2,929 10.07 20.76 69.17
2009 1,682 7.67 17.66 74.67
Source: Banco de Dados Judicialização, GPES/UFMG, 2018
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Figure 1 – Proportion of judicialized medicines, per year, according to the classification of adequacy to the 
criteria for access to the pharmaceutical assistance, Minas Gerais, 2003-2009
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Source: Banco de Dados Judicialização, GPES/UFMG, 2018
Discussion
The results of this study show that the definition 
of the outlines of comprehensiveness by Law 
no. 12,401/2011 and universal and equal access 
to the pharmaceutical assistance by Decree no. 
7,508/2011 could lead to a significant reduction in 
the judicialization of health care, if the Judiciary 
guided its actions based on the criteria set out 
in such legislations. If, between 1999 and 2009, 
such parameters were respected by the Judiciary, 
at least 68.84% of the judicialized medicines 
in Minas Gerais would have been deferred. The 
temporal analysis from 2003 to 2009 shows the 
possibility of increasing this proportion when 
more information is available. By analyzing only 
the medicines to which it was possible to assign at 
least one information about their prescription, the 
percentage of inadequacy to the criteria increased 
to 85.77%, confirming the importance of having 
detailed information about the judicialization of 
health care for its deep knowledge.
Due to the lack of national data that can offer a 
Brazilian overview for judicialization, we believe that 
the results in Minas Gerais, the second state with 
more lawsuits in health care (Aumentam…, 2017), 
may reflect the relevance of the impact generated 
by the observance of Law no. 12,401/2011 and Decree 
no. 7,508/2011 by the Judiciary.
However, we do not know to what extent the 
parameters established in 2011 were incorporated 
by the legal practitioners, and further research with 
updated data need to be conducted. Recent studies 
indicate that decisions in disagreement with public 
policies are still being made (Asensi; Pinheiro, 2016; 
Guimarães, 2014; Siqueira, 2015), which suggests 
that the legislations addressed in this study did 
not influence a decisive judicial action. In 2015, 
after evaluating legal proceedings complied by the 
State Secretariat of Health of São Paulo, Siqueira 
(2015) found that 69% of the prescriptions in the 
processes came from the private health network. In 
addition, the author showed that, although Rename 
2013 includes 884 medicines offered to meet the 
needs for 99% of diseases, 93% of the judicialized 
medicines in the state were not covered by SUS and 
the 7% covered were not in compliance with PCDT 
(Siqueira, 2015).
For Guimarães (2014), one of the possible 
explanations for the failure to comply with the 
legislations by the Judiciary is the dubiousness of the 
conclusions issued by the final report of the Public 
Hearing of 2009, which recognizes the legitimacy 
and accountability of SUS to decide what will be 
offered and under what conditions, but at the same 
time, it assumes the prerogative of Judicial decisions 
against the guidelines of public health policy. The 
author suspects that there is no big “doctrinal and 
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pedagogical” effort for the proper dissemination of 
Law no. 12,401/2011, including the managers of SUS.
Also, the historic moment of the prominence of 
the Judiciary must be considered (Guimarães, 2014), 
which, according to Asensi and Pinheiro (2016), is 
more similar to a health policy. Guimarães (2014) 
highlights an increasing trend to transfer political 
decisions to the legal sphere, including the scope 
of the evaluation and incorporation of health 
technologies. When discussing the challenges 
of political incorporation of technologies in 
SUS, the author indicates that, according to the 
international experience, the success of agencies 
of health technology assessment (ATS) such as 
Conitec, created by Law no. 12,401/2011, depends 
significantly on its public recognition and prestige, 
such as what happens with the National Institute 
for Health and Care Excellence (Nice) in England. 
In Brazil, however, despite Conitec being a national 
reference agency in ATS, the National Justice Council 
(CNJ) has a parallel project financially supported by 
the Ministry of Health, regarding the creation of 
a database of technical notes on health drawn up 
by Technical Support Centers to subsidize judicial 
decisions only (CNJ…, 2016).
In this context, we should consider that, although 
the creation of Conitec means a breakthrough for 
health policy in Brazil, it has not yet achieved the 
“methodological development and broad scientific 
legitimacy and potential for comprehensive 
political action” (Novaes; Soárez, 2016, p. S11). For 
institutional strengthening, Conitec needs funds 
for the maintenance of a technical framework of 
stable and qualified human resources; greater 
transparency in the processes and decisions, 
including prioritization criteria of evaluations; 
promotion of greater involvement and clarification 
of civil society and greater independence; as well 
as the development of more rigorous research 
(Guimarães, 2014; Novaes; Soárez, 2016).
Final considerations
Once the importance of a robust policy of ATS in 
a context of intense judicialization and technology 
imperative is recognized (Andrade et al., 2008; 
Guimarães, 2014), a question needs to be answered: 
instead of creating and supporting a parallel network 
of health technology analysis centered on CNJ, would 
it not be more appropriate for such efforts to focus 
on the improvement and strengthening of the policy 
of ATS of SUS itself, such as Conitec?
In this scenario of prominence of the Judiciary, 
the decisions taken by the Justice System for 
the confrontation of judicialization can find 
more supporters than the decisions taken by 
the parliamentary system, as is the case of the 
legislations in question.
Bittencourt (2016, p. 107) indicates that, currently, 
the judicialization of health represents “not only a 
conflict, but also a sociopolitical phenomenon,” and 
all its complexity, its impact, as well as the responses 
of institutional powers (whether the Judiciary or 
Parliamentary systems) should be carefully analyzed. 
In this context, the results of this study indicate the 
Law no. 12,401/2011 and Decree no. 7,508/2011 as 
potential tools for streamlining the judicialization 
of health in the country.
However, to streamline judicialization does not 
automatically approach the State to the implementation 
of the right to health in the constitutional provisions. 
The streamlining potential of the criteria established 
in 2011 for universal access and comprehensive 
pharmaceutical assistance goes through definitions 
of the principles of SUS that can, at some extent, 
drive the health policy away from the constitutional 
landmark. Thus, a thorough reflection should be made 
about the impacts of defining the judicial activity in 
health care by such criteria, and further studies must 
be carried out on the subject.
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